Evolent Health - Class A opened lower at $4.96, compared with its previous close of $4.99. In the last trading session, the stock traded between $4.65 and $4.99. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Evolent Health - Class A is now worth
$ 16.63
Resulting in a loss of
$ 83.37 (83.37%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 7 Analysts
Buy
85.71%
Hold
14.29%
Sell
0%
Markets Today
Today's Change
$-0.23 (-4.51%)
Day High
$4.99
Day Low
$4.65
Day Open
$4.96
Prev Close
$4.99
Volume
11,47,801
1W Return
-0.63%
1M Return
12.46%
3M Return
16.13%
6M Return
20.33%
1Y Return
-5.46%
Fundamentals
Market Cap ($ Mn)
539
PE Ratio
-
PB Ratio
1.35
PEG Ratio
-
ROE
-65.34%
ROCE
-26.20%
EPS (TTM)
$-0.21
Investment Returns
1 Week
-0.63%
1 Month
12.46%
3 Months
16.13%
6 Months
20.33%
9 Months
78.46%
Financials
Quarterly
All values in $ Mn
444.3
Jun 25
479.5
Sep 25
468.7
Dec 25
496.2
Mar 26
652.5
Jun 26
725.4
Sep 26
Updates
6Nov
Oppenheimer raises Evolent Health price target to $7, keeps Outperform
Oppenheimer maintains an Outperform rating on Evolent Health. Price target increased from $6 to $7. Analyst Michael Wiederhorn issued the update.
6 days ago
18Aug
JP Morgan raises Evolent Health price target to $6, maintains Overweight
JP Morgan analyst John Stansel maintains an Overweight rating on Evolent Health (NYSE: EVH) and raises the price target from $5 to $6. The move signals sustained confidence in the stock's valuation, with no accompanying changes to the rating status.
2mo ago
23Jul
Citigroup downgrades Evolent Health to Neutral, raises target to $6.75
Citigroup analyst Daniel Grosslight downgraded Evolent Health from Buy to Neutral and raised the price target to $6.75 from $5.5. Separately, Canaccord Genuity analyst Richard Close maintained a Buy rating with a price target of $7. The differing analyst views present a mixed outlook for the NYSE-listed healthcare company.
3mo ago
9Jul
Evolent Health to release Q2FY26 results on August 6
Evolent Health, Inc. will announce its Q2FY26 financial results on August 6, 2026, before market open, followed by a conference call at 8 a.m. ET. Shareholders and analysts can access the call via the company's investor relations website, with audio playback available for 90 days.
4mo ago
30Jun
Truist downgrades Evolent Health to Hold, keeps target at $7
Truist Securities analyst Jailendra Singh downgraded Evolent Health from Buy to Hold while keeping the price target steady at $7.
4mo ago
12Jun
Truist Securities raises Evolent Health price target to $7
Truist Securities analyst Jailendra Singh maintained a Buy rating on Evolent Health and raised the price target from $6 to $7, indicating a positive outlook for the NYSE-listed stock.
